Lead front-line targeted therapies for CLL include small-molecule inhibitors that either target BCR signaling through the inhibition of Bruton’s tyrosine kinase (BTK), such as ibrutinib, or target apoptosis mechanisms such as the BCL2 antagonist, venetoclax [1]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.